Pharming Group NV (PHAR): Price and Financial Metrics

Pharming Group NV (PHAR): $9.69

0.23 (-2.32%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add PHAR to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of 481

in industry

PHAR Price/Volume Stats

Current price $9.69 52-week high $16.71
Prev. close $9.92 52-week low $9.27
Day low $9.69 Volume 255
Day high $9.69 Avg. volume 2,589
50-day MA $11.16 Dividend yield N/A
200-day MA $11.79 Market Cap 650.27M

PHAR Stock Price Chart Interactive Chart >


Pharming Group NV (PHAR) Company Bio


Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.


PHAR Latest News Stream


Event/Time News Detail
Loading, please wait...

PHAR Latest Social Stream


Loading social stream, please wait...

View Full PHAR Social Stream

Latest PHAR News From Around the Web

Below are the latest news stories about PHARMING GROUP NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today the expansion of its rare disease pipeline with plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming has engaged wit

Yahoo | December 13, 2023

Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective p

Yahoo | November 21, 2023

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval

Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the timetab

Yahoo | November 10, 2023

Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting

Leiden, The Netherlands, November 7, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November. IPIC, Rotterdam, The Netherlands, November 8 - 10, 2023 Approaches to family testing for auto

Yahoo | November 7, 2023

Pharming Group to participate in November investor conferences

Leiden, The Netherlands, November 1, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of November: Stifel 2023 Healthcare Conference, New York, November 14-15Anurag Relan, Chief Medical Officer will participate in a fireside chat, question and answer session on Tuesday, November 14 at 08:35 am ET/14:35 CET.Jefferies London Healthcare Conference 2023, London, U.K

Yahoo | November 1, 2023

Read More 'PHAR' Stories Here

PHAR Price Returns

1-mo -14.02%
3-mo -19.08%
6-mo -11.26%
1-year N/A
3-year -24.94%
5-year N/A
YTD -15.22%
2023 3.63%
2022 23.38%
2021 -41.16%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!